SNGXW Projected Dividend Yield
Soligenix Inc ( NASDAQ : SNGXW )Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases. Co.'s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) for the treatment of cutaneous T-cell lymphoma, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders. Co.'s Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and other infectious disease. 20 YEAR PERFORMANCE RESULTS |
SNGXW Dividend History Detail SNGXW Dividend News SNGXW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |